Rogers, Brooke G.
Sosnowy, C.
Zanowick-Marr, A.
Chan, P. A.
Mena, L. A.
Patel, R. R.
Goedel, W. C.
Arnold, T.
Chu, C.
Galipeau, D.
Montgomery, M. C.
Curoe, K.
Underwood, A.
Villalobos, J.
Gomillia, C.
Nunn, A. S.
Funding for this research was provided by:
National Institutes of Mental Health (5R01MH114657-02, 5R01MH114657-02, 5R01MH114657-02, 5R01MH114657-02, 5R01MH114657-02, R25MH083620, 5R01MH114657-02)
Providence/Boston Center for AIDS Research (P30AI042853, P30AI042853)
National Institute of Mental Health (K23MH124539-01A1)
Article History
Received: 26 February 2022
Accepted: 29 July 2022
First Online: 5 August 2022
Declarations
:
: All methods were carried out in accordance with relevant guidelines and regulations. Study procedures were approved by Institutional Review Boards at The Miriam Hospital, The University of Mississippi Medical Center, and Washington University School of Medicine. Written informed consent was obtained from all participants and/or their legal guardian(s).
: Not applicable.
: B.G.R. co-leads a Gilead Sciences grant to provide PrEP within the Rhode Island Department of Corrections: #IN-US-276-5463. Dr. Philip Chan is staff at Rhode Island Public Health Institute and consults for Rhode Island Department of Health. Dr. Leandro A. Mena reports the following consultant and research grants from Gilead Sciences, ViiV Healthcare/Glaxo-Smith Kline, Merck, Roche and research grants from TaiMed and Janssen. All other authors declare no competing interests.